I wonder if the target is Tecentriq . It's interesting that the wording in regards to the Enhanze royalties is slightly different in each press release - "tiered, mid-single digit" for Roche, not specified for BMY etc.
"Bristol-Myers Squibb will pay Halozyme royalties on sales of products using the ENHANZE technology developed under the collaboration."
"Under terms of the agreement, Halozyme will receive an initial $30 million with the potential to earn additional payments of up to $160 million subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive tiered, mid-single digit royalties on sales of commercialized products."
More importantly, the market is starting to realize that we may soon have a second SC formulation in phase 3, Opdivo and perhaps Tecentriq in the clinic soon, and so on.
An Italian expression comes to mind -- Enhanze may soon become "Just like parsley."
News 
Market Data 
Discover 
